

Reference:	FOI.12705.23
Subject:	Primary Care rebates
Date of Request:	20 September 2023

Requested:

1. Please can you provide the product names with start and finish dates of all your agreed primary care rebates?
Please can you provide this information at Health Board level
2. Please can you advise if any of your agreed rebates are conditional on achieving increased volumes/ market shares?
3. Please can you also provide a copy of your Health Board primary care rebate policy.

Response:

1. Hywel Dda University Health Board (UHB) provides, within the table overleaf, the current rebate product, company name, start and end dates.

Where no end date is stipulated, the rebate agreement remains open ended.

Rebate	Company	Start	End
Abtard	Ethypharm UK Ltd	Oct-15	
Accu-Chek	Roche Diabetes Care Limited	Apr-21	Sep-23
Adcal D3	Kyowa Kirin Ltd	Jan-16	
Aimovig	Novartis Pharmaceuticals Ltd	Apr-21	Mar-24
Ajovy	Teva UK Ltd	Apr-23	Mar-25
Alzest	Dr Reddys Laboratories (UK) Ltd	Oct-22	Sep-23
Amgevita	Amgen	Oct-22	Sep-25
Aproderm	Fontus Health	Jan-20	Sep-23
Balneum	Almirall	Oct-21	Sep-23
BD Viva Needles	Beckton, Dickinson UK Ltd	Apr-23	Mar-25
Bupeaze	Dr Reddys Laboratories (UK) Ltd	Oct-22	Sep-23
Buvidal	Camurus	Oct-22	Jun-24
Cetraben 3	Thornton & Ross	Jan-22	Dec-23
Cosentyx	Novartis Pharmaceuticals Ltd	Apr-23	Dec-25
Cynril	Fontus Health	Apr-20	Mar-25
Edoxaban	Daiichi Sankyo UK Ltd	Jan-23	Dec-24
Epesri	Strides Pharma UK Ltd	Apr-22	Mar-24
Epidyolex	GW Pharma Limited	Oct-21	Sep-24
Espranor	Ethypharm UK Ltd	Jan-22	Dec-24
Evrenzo	Astellas Pharma Europe Ltd	Jan-23	Dec-25
Fencino 2	Luye Pharma	Jan-23	
Firmagon	Ferring	Oct-19	Dec-23
Fixkoh - 2	Thornton & Ross	Oct-21	Mar-25
Fostair pMDI	Chiesi Ltd	Jul-21	Sep-23

Glucophage SR	Merck Serono Limited	Jan-22	Dec-23
Hanixol	Fontus Health	Jan-20	Dec-24
Hylo Fresh	Scope Ophthalmics Ltd	Apr-22	Mar-25
Hylo Night Ointment	Scope Ophthalmics Ltd	Apr-22	Mar-25
Jyseleca	Galapagos Biotech Ltd	Oct-21	Dec-23
Ledraxen	Tetris Pharma Ltd	Jan-22	Dec-23
Legvio	Novartis Pharmaceuticals Ltd	Jan-22	Dec-24
Lumecare	Medicom Healthcare Ltd	Jan-20	Jun-24
Luventa	Fontus Health	Oct-15	
NILEMDO & NUSTENDI	Daiichi Sankyo UK Ltd	Apr-21	Mar-31
Olumiant	Eli Lilly and Company Limited	Oct-17	Sep-23
Omnitrope SurePal	Sandoz	Jul-21	Jun-24
OneTouch	Lifescan UK	Apr-22	Mar-24
Ongentys	BIAL - Portela & C ^a , S.A.	Oct-20	Sep-23
Orencia	Bristol-Myers Squibb Pharmaceuticals Limited	Apr-20	Mar-24
Orobalin	Northumbria Pharma Ltd	Jan-21	Dec-23
Otezla	Amgen	Jan-23	Dec-25
Physeptone	Ethypharm UK Ltd	Oct-21	Sep-24
Pipexus	Ethypharm UK Ltd	Jul-18	
Praluent	Aventis Pharma Limited T/A Sanofi	Oct-22	Dec-24
Prostap DCS	Takeda	Apr-17	
Ranexa	A.Menarini Farmaceutica Internazionale SRL	Oct-22	Sep-24
Repatha	Amgen	Jul-18	
Resource Thicken Up Clear	Nestle UK Ltd	Jan-21	Jun-24
Revolade	Novartis Pharmaceuticals Ltd	Jan-22	Dec-23
Rinvoq	AbbVie Limited	Oct-21	Sep-23
Saxenda	Novo Nordisk	Jan-21	
Sirdupla	Viatrix UK Healthcare Limited	Apr-23	Mar-24
Slenyto	Flynn Pharma	Apr-21	Mar-24
Sprycel (Dasatinib)	Bristol-Myers Squibb Pharmaceuticals Limited	Jul-18	
Strivit-D3	Strides Pharma UK Ltd	Apr-19	Mar-24
Tasigna	Novartis Pharmaceuticals Ltd	Jul-22	Dec-23
Tolthen XL	Northumbria Pharma Ltd	Oct-21	Sep-23
Vliwasorb Pro	Lohmann & Rauscher	Jul-22	Jun-24
WaveSense JAZZ	AgaMatrix Europe Ltd	Apr-21	Sep-23
WockAIR	Wockhardt UK Ltd	Apr-22	Mar-24
Xaggitin	Ethypharm UK Ltd	Apr-17	
Xailin	Visufarma	Jul-22	Jun-24
Xarelto	Bayer	Oct-20	Mar-24
Xolair	Novartis Pharmaceuticals Ltd	Apr-23	Dec-25
Xtandi	Astellas Pharma Europe Ltd	Oct-21	Sep-25
Zaluron XL	Fontus Health	Oct-15	
Zoladex 2.1	AstraZeneca UK Limited	Jan-23	Dec-23

2. The UHB confirms that none of its agreed rebates are conditional on achieving increased volumes/market shares.
3. The UHB regrets to inform you that it does not hold the information requested.